A note for UK readers

This page explains Japan’s system. Its licences, funding rules and prescribing criteria do not determine access in the UK.

Is BMI alone enough to establish insured access?

No. The official pathway also addresses associated disease, previous management and the suitability of the treating institution.

Use Japan's own criteria

The Ministry of Health, Labour and Welfare publishes optimal-use guidance for Wegovy in obesity treatment and updated it in June 2026. The pathway is more specific than a general international description of who might benefit from a GLP-1 medicine.

The institution is part of eligibility

Insurance guidance directs use in medical institutions meeting defined requirements and able to respond to adverse effects. A medicine being authorised does not mean any clinic or prescription automatically qualifies for insured treatment.

Clarify insured and self-pay care

Ask the service which pathway it offers, which criteria it will assess and which charges fall to you. Obtain the expected JPY payment for consultations and medicine together; do not compare an insured personal payment with an unqualified private package.

How this informs UK readers

Japan illustrates that a treatment pathway can specify the service as well as the patient. Its thresholds and insurance rules should not be copied into a UK eligibility checker. A UK assessment must use the relevant UK medicine information and NHS or private-care pathway.

Keep these four questions separate

Access

Japanese clinical and medical-institution requirements

Funding

Insurance conditions linked to optimal-use guidance

Cost context

JPY insurance payments do not represent UK costs

Regulatory source

MHLW and PMDA

Compare health systems ↗
Follow the evidence

Sources & further reading

Sources checked . These links support the information above; they do not imply endorsement of this website.

  1. MHLW: June 2026 revision of Wegovy optimal-use guidance
  2. MHLW: insurance requirements for Wegovy obesity treatment
A note on this guide

Written for a UK audience by the Health Comparisons editorial team. This page is an information resource and has not been presented as a clinician’s personal recommendation. Discuss treatment decisions with your prescriber.

Read our editorial standards →